New hope for hard-to-treat prostate cancer? early trial combines two therapies
NCT ID NCT07389187
First seen Feb 05, 2026 · Last updated May 22, 2026 · Updated 17 times
Summary
This early-phase study tests a new drug (LC-K76) combined with an immunotherapy (anti-PD-1) and hormone therapy in 10 men whose metastatic prostate cancer has worsened after standard treatments. The main goal is to check safety, with early signs of tumor control also measured. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MCRPC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Changzheng hospital
Shanghai, Shanghai Municipality, 201109, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.